Major determinants and possible mechanism of dobutamine-induced left ventricular outflow tract obstruction in patients with a sigmoid ventricular septum  by Tano, Ayako et al.
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Background:  A  sigmoid  ventricular  septum  (SVS)  may  be related  to normal  aging,  but some  people  with
an SVS  develop  a left ventricular  outﬂow  tract  (LVOT)  obstruction  (deﬁned  as  a gradient  of >30  mmHg).
Therefore,  we  investigated  the  association  of LVOT  obstructions  with  an SVS  by  dobutamine  stress  echo-
cardiography  (DSE)  and  assessed  the  possible  mechanism  of  the  latent  LVOT  obstruction.
Methods  and  results:  DSE  was  performed  in 64  subjects  with  SVS (mean  age: 73.3  ±  7.7 years;  36 women)
without  an  LVOT  obstruction.  In  40 of  the 64  subjects,  an  LVOT  obstruction  occurred  during  the  DSE
(deﬁned  as  latent  obstruction).  At rest,  the  subjects  with  a latent  obstruction  had  a shorter  end-systolic
mitral  leaﬂet  tethering  distance  (“˛” distance,  i.e.  the distance  between  the  tip of the  posterior  papillary
muscle  and  the  contralateral  anterior  mitral  annulus)  than  those  without  one (29.9  ±  4.2  mm  versus
35.2  ±  4.6  mm),  as well  as a  smaller  end-systolic  LVOT  diameter  (13.4  ± 2.7 mm  versus  16.1  ± 3.4  mm)  and
larger ejection  fraction  (72.0  ±  5.0%  versus  67.8  ± 5.9%)  (all  p < 0.05).  They  also  had  a higher  LV  outﬂow
velocity  at  rest  (1.23  ± 0.24  m/s  versus  1.03  ± 0.24 m/s)  and  during  the  Valsalva  maneuver  (1.31  ±  0.27  m/s
versus 1.03  ±  0.27 m/s)  (both  p <  0.05).  After  adjusting  for these  parameters,  the resting  end-systolic  “˛”
distance  and  LV  outﬂow  velocity  at rest  remained  independent  predictors  of  a  latent  obstruction.
Conclusion:  A  short  leaﬂet  tethering  distance  (“˛”)  was  the  major  determinant  of  a latent  obstruction,
suggesting  that  a mitral  leaﬂet  displacement/redundancy  caused  by a short  “˛”  distance  contributes  to
the LVOT  obstruction.
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A sigmoid ventricular septum (SVS) is considered to be related
o the normal aging process and has not been reported to be asso-
iated with an adverse prognosis [1–3]. However, a left ventricular
utﬂow tract (LVOT) obstruction can occur in persons with an SVS
4,5]. According to one report, about 50% of persons with an SVS
ave an excessive response to dobutamine and develop an LVOT
bstruction even in the absence of regional left ventricular wall
otion abnormalities, i.e. so-called “latent LVOT obstruction” [6]. In
atients with hypertrophic obstructive cardiomyopathy (HOCM),
hich is well known to cause LVOT obstructions, the mechanism of
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E-mail address: kasamaki.yuuji@nihon-u.ac.jp (Y. Kasamaki).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
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the obstruction has been investigated extensively [7–15]. However,
little is known regarding the mechanism of latent LVOT obstruc-
tions associated with SVS. Therefore, the objectives of the present
study were: (1) to investigate the occurrence of LVOT obstructions
in persons with SVS during dobutamine stress echocardiography
(DSE); (2) to determine the predictors of latent LVOT obstructions;
and (3) to identify the possible mechanisms of latent obstructions.
Methods
Study population
We  screened 78 consecutive patients who  had SVS together
with various cardiac symptoms [41 patients (53%)], any elec-
trocardiographic (ECG) abnormalities [44 patients (56%)] and/or
cardiothoracic ratio ≥50% on the chest X-ray [18 patients (23%)],
and who  were referred to our echocardiography laboratory from
vier Ltd. All rights reserved.
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eptember 2009 to August 2010. Fourteen patients met  the exclu-
ion criteria described below, so the remaining 64 patients (36
omen and 28 men; mean age: 73.3 ± 7.7 years) underwent DSE
o investigate the occurrence of an LVOT obstruction. Detection
f an SVS was  based upon a quantitative assessment by sonog-
aphers and cardiologists with more than 5 years of experience.
e deﬁned the SVS according to the following criteria [3,7]: (1) an
pper interventricular septal thickness ≥14 mm;  (2) an upper sep-
al thickness/mid-septal thickness ratio ≥1.3; (3) an angle between
he anterior wall of the aorta and right ventricular side of the inter-
entricular septum (septal ) <120◦ in the parasternal long-axis
iew; and (4) no wall motion abnormalities or mid-septal scar-
ing that could result in isolated septal thickening. The exclusion
riteria were: (1) an asymmetric septal hypertrophy (mid-septal
hickness/posterior wall thickness ratio ≥1.3); (2) valvular heart
isease (moderate to severe mitral or tricuspid regurgitation with
 regurgitant fraction >20%, severe aortic regurgitation with a steep
et deceleration rate <200 ms,  or aortic stenosis with an aortic
alve area <3.0 cm2); (3) an implanted pacemaker; (4) ischemic
eart disease (detected by an exercise stress test, computed tomo-
raphy angiography, or pharmacological/exercise stress thallium
cintigraphy; (5) a history of a cerebral or aortic aneurysm; (6)
n age >90 years; (7) global or local abnormalities of the left
entricular contraction; and 8) poor quality echocardiographic
mages. This study was  approved by our institutional human
esearch committee (Nihon University Itabashi Hospital Review
oard).
ig. 1. Representative example of a sigmoid ventricular septum patient with a latent left v
iographic parameters in the parasternal long-axis view and enlarged view of the LVOT (
C).  (A) The septal angle “” is the angle between the anterior wall of the aorta and the rig
idirectional red, yellow, and white arrows indicate the mid-IVS, upper IVS, and LVOT d
istance between the tip of the posterior papillary muscle and the contralateral anterior
eferences to color in this ﬁgure legend, the reader is referred to the web  version of this alogy 61 (2013) 428–435 429
Dobutamine stress echocardiography
DSE was performed as reported previously [16]. In brief, as the
12-lead ECG and blood pressure were monitored, dobutamine was
infused at an initial rate of 10 g/kg/min, which was subsequently
increased to 20, 30, and 40 g/kg/min every 3 min. At baseline, both
the general echocardiographic parameters and the following spe-
ciﬁc parameters were measured: (a) upper and mid  interventricular
septal thickness at the end-diastolic phase; (b) LVOT diameter; (c)
septal  (Fig. 1A); and (d) the mitral leaﬂet tethering distance (“˛”,
deﬁned as the distance from the tip of the posterior papillary mus-
cle to the contralateral anterior part of the mitral annulus in the
apical three-chamber view) (Fig. 1B and C). These speciﬁc param-
eters were measured at both end-systole and end-diastole. The LV
ejection fraction (EF) was measured by biplane Simpson’s method.
In addition, we  measured the LV posterior wall thickness (PWT),
relative wall thickness (RWT), and LV mass (LVM = 0.8 × (1.04
([LV end-diastolic dimension (LVEDD) + PWT  + mid  interventricu-
lar septal thickness]3 − [LVEDD]3)) + 0.6 (g)). The LV mass index
(LVMI) was  calculated by the LVM/body surface area. The RWT  was
measured as 2 × PWT  divided by the LVEDD.
The LVOT velocity was  measured at rest and during the Val-
salva maneuver by pulsed Doppler echocardiography (Fig. 2A and
C). During a dobutamine infusion at each rate (10–40 mg/kg/min),
the LVOT velocity was  measured by continuous Doppler echo-
cardiography. When the LVOT velocity reached more than 1 m/s,
the LVOT pressure gradient was estimated using the simpli-
entricular outﬂow tract (LVOT) obstruction. Measurement of the baseline echocar-
A), as well as in the apical three-chamber view at end-diastole (B) and end-systole
ht ventricular side of the interventricular septum (IVS) at end-diastolic phase. The
iameter, respectively. (B and C) The leaﬂet tethering distance “˛” is deﬁned as the
 part of the mitral annulus (bidirectional purple arrow). (For interpretation of the
rticle.)
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Fig. 2. Example of a sigmoid ventricular septum with a left ventricular outﬂow tract (LVOT) obstruction during dobutamine stress echocardiography. A baseline pulsed-wave
Doppler recording shows a peak velocity of 0.89 m/s  (no signiﬁcant LVOT pressure gradient) at the LVOT (A), while the M-mode echocardiogram reveals a normal mitral
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salve  movement (B). After a 20 g/kg/min dobutamine infusion, continuous wave D
23.82  mmHg) (C) and systolic anterior motion (SAM) of the mitral leaﬂet that is co
ed Bernoulli equation (gradient [mmHg] = 4′ [peak velocity]2)
Fig. 2). An LVOT obstruction was deﬁned as a gradient >30 mmHg
16–18]. DSE was terminated under any of the following con-
itions: on reaching the maximum dose of dobutamine; if an
VOT obstruction was consistently observed by continuous Doppler
chocardiography; if there was deterioration of the left ventricu-
ar wall motion; or if there was ST depression >2 mm,  severe chest
ain, dangerous arrhythmias, or severe hypotension (systolic blood
ressure <80 mmHg) or hypertension (systolic blood pressure
220 mmHg).
ssessment of the mitral leaﬂet tethering distance (“˛” distance)
y real-time 3-dimensional echocardiography
The end-systolic “˛” distance was measured by real-time
-dimensional (RT3D) echocardiography (Vivid 7, GE Vingmed
ltrasound, Horten, Norway) in 11 subjects to conﬁrm the accu-
acy of the “˛” distance measured on 2-dimensional images in the
pical 3-chamber view (Fig. 3). RT3D images were obtained through
n apical window and were gathered over 4 cardiac cycles during
nd-expiration. The data were analyzed off-line with commercial
oftware (EchoPAC, GE Vingmed Ultrasound, version 108.0.1). The
ip of the posterior papillary muscle and the contralateral ante-
ior part of the mitral annulus were carefully marked on moving
mages in the short-axis view displayed with RT3D left ventricular
olume data (Fig. 3). A speciﬁc 3-chamber view including the two
arked sites was obtained, after which two experienced sonog-
aphers and cardiologists measured the end-systolic “˛” distance
etween these two sites, while blinded to the “˛” distance mea-
ured on 2-dimensional images.r reveals a peak velocity of 5.56 m/s (an estimated peak LVOT pressure gradient of
nt with an LVOT obstruction (D).
Impact of beta-blockers on latent LVOT obstructions associated
with an SVS
Eight of the SVS patients with latent LVOT obstructions were
treated with a beta-blocker after the DSE because they had promi-
nent symptoms. At least one month after starting the beta-blocker
therapy, an evaluation of the cardiac symptoms and the DSE were
repeated and the results were compared with the baseline data.
Statistical analysis
The results are expressed as the mean ± SD. Between-group
comparisons were done with a paired or unpaired Student’s t-test.
The chi-squared test was  used to assess the differences in the nom-
inal variables. The variables that were signiﬁcantly related to an
LVOT obstruction (LVEF, LVOT velocity, LVOT diameter, and “˛”
distance) were entered into the multivariate logistic regression
model. Bland and Altman plots with 95% limits of agreement were
used to assess the interobserver and intraobserver reproducibility
of the “˛” distance and the agreement between the 2D-based and
RT3D-based “˛” distances. Statistical signiﬁcance was accepted at a
p < 0.05. All statistical analyses were performed with JMP  8 software
(SAS Institute, Cary, NC, USA).
Results
Baseline characteristics and echocardiographic parameters for
SVS with and without latent LVOT obstructions
Tables 1 and 2 show the baseline characteristics and echocar-
diographic parameters for an SVS with and without a latent LVOT
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Fig. 3. Example of the real-time 3-dimensional (RT3D) measurement of the “˛” distance. The yellow arrow and red dot indicate the tip of the posterior papillary muscle
and  the contralateral anterior mitral annulus, respectively, established on the moving image in each short-axis view (middle right and bottom panels). The end-systolic “˛”
distance was measured in the speciﬁc apical 3-chamber view, which was  derived from the plane including the yellow arrow and red dot (middle left panel). The upper panels
show  the RT3D images obtained in systole and diastole. RA, right atrium; LA, left atrium; LVOT, left ventricular outﬂow tract. (For interpretation of the references to color in
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bstruction. Among the 64 subjects in the SVS group, 40 (63%)
eveloped an LVOT obstruction during the DSE (latent obstruc-
ion), with a peak gradient of 114 ± 75 (33–288) mmHg. Among
hese 40 subjects, a latent obstruction was induced by the infusion
f dobutamine at 10 g/kg/min in 8 subjects (20%) at 20 g/kg/min
n 21 subjects (53%), at 30 g/kg/min in 9 subjects (23%), and at
0 g/kg/min in 2 subjects (5%). There were no signiﬁcant differ-
nces in the baseline characteristics between the subjects with
nd without latent obstructions (Table 1). Examples of represen-
ative echocardiographic parameters in SVS patients with a latent
VOT obstruction are shown in Fig. 1A–C. Subjects with a latent
VOT obstruction had a shorter end-systolic mitral leaﬂet tether-
ng distance (“˛”) than those without it (29.9 ± 4.2 mm versus
5.2 ± 4.6 mm,  p < 0.0001), as well as more marked narrowing of
he LVOT during end-systole, a larger LVEF, and a higher LV out-
ow velocity both at rest and at during the Valsalva maneuver
shown in Table 2, p < 0.05 for all). There were no statistically sig-
iﬁcant differences in the other parameters including the PWT,
WT, and LVMI between the two groups (PWT: 9.8 ± 1.8 mm versus
.5 ± 1.3 mm,  p = 0.4397; RWT: 0.41 ± 0.08 versus 0.39 ± 0.66 mm,
 = 0.3180; LVMI: 109 ± 32 g/m2 versus 106 ± 27 g/m2, p = 0.7275).After adjusting for the variables with a statistical signiﬁcance,
the systolic distance “˛” and LVOT velocity at rest were still
independent predictors of a latent LVOT obstruction during the DSE
(“˛”: odds ratio [OR] 1.31, 95% conﬁdence interval [CI] 1.11–1.61,
p = 0.0037; LVOT velocity: OR 0.01, 95% CI 0–0.40, p = 0.0280).
However, the other parameters did not show any signiﬁcance as
predictors of a latent obstruction (LVEF: OR 0.91, 95% CI 0.79–1.03,
p = 0.1571; end-systolic LVOT diameter: OR 1.18, 95% CI 0.93–1.57,
p = 0.2109).
DSE ﬁndings in subjects with and without LVOT obstruction
Examples of echocardiographic images obtained during the DSE
are shown in Fig. 2A–D, and Table 3 shows the clinical parameters
and the occurrence of systolic anterior motion (SAM) during the
DSE. There were no signiﬁcant differences in the resting or peak
heart rates between the subjects with and without latent LVOT
obstructions. Although there was no signiﬁcant difference in the
baseline blood pressure, the peak blood pressure was  signiﬁcantly
lower in the subjects with a latent obstruction than in those without
a latent obstruction, and this was  possibly related to the occurrence
432 A. Tano et al. / Journal of Cardiology 61 (2013) 428–435
Table 1
Clinical characteristics of patients with and without latent LVOT obstructions.
All (n = 64) Latent LVOT obstruction (+) (n = 40) Latent LVOT obstruction (−) (n = 24) p-Value
Age, years 73.3 ± 7.7 73.3 ± 8.5 73.2 ± 6.5 0.94
Female (%) 36 (56) 24 (60) 12 (50) 0.44
Height, cm 156 ± 8.8 156.6 ± 8.9 155.2 ± 8.8 0.54
Weight, kg 58.1 ± 10.9 58.6 ± 12 57.3 ± 9.9 0.64
BMI,  kg/m2 23.7 ± 3.1 23.7 ± 3.2 23.7 ± 3.1 0.99
Resting HR, bpm 65 ± 9.1 67 ± 8.7 63 ± 9.6 0.12
Systolic BP, mmHg  134 ± 20 135 ± 17 133 ± 24 0.71
Diastolic BP, mmHg 77 ± 12 78 ± 12 74 ± 13 0.21
Cardiovascular risk factors
Hypertension (%) 47 (73) 32 (80) 15 (63) 0.13
Dyslipidemia (%) 22 (34) 16 (40) 6 (25) 0.22
Diabetes mellitus (%) 10 (16) 5 (13) 5 (21) 0.38
Symptoms
Dyspnea (%) 6 (9) 4 (10) 2 (8) 0.82
Chest  pain (%) 16 (25) 13 (33) 3 (13) 0.06
Syncope/presyncope (%) 14 (22) 10 (25) 4 (17) 0.43
Palpitations (%) 10 (16) 4 (10) 6 (25) 0.12
Others (%) 7 (11) 5 (13) 2 (8) 0.60
No  symptoms (%) 23 (36) 16 (40) 11 (46) 0.38
Medications
Calcium antagonists (%) 37 (58) 24 (60) 13 (54) 0.65
ACEI/ARB (%) 33 (52) 24 (60) 9 (38) 0.08
Diuretics (%) 9 (14) 6 (15) 3 (13) 0.78
Beta-blockers (%) 6 (9) 4 (10) 2 (8) 0.82
ECG  abnormality
Left ventricular hypertrophy (%) 18 (28) 10 (25) 8 (33) 0.48
Conduction abnormalitya (%) 14 (22) 7 (18) 7 (29) 0.28
Non-speciﬁc ST or T abnormality (%) 6 (9) 3 (8) 3 (13) 0.51
PVC  or PAC (%) 3 (5) 2 (5) 1 (4) 0.88
Others (%) 3 (5) 2 (5) 1 (4) 0.88
CTR  >50% (%) 18 (28) 12 (30) 6 (25) 0.67
LVOT, left ventricular outﬂow tract; BMI, body mass index; HR, heart rate; BP, blood pressure; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor
blockers; ECG, electrocardiogram; PVC, premature ventricular contraction; PAC, premature atrial contraction; CTR, cardiothoracic ratio.
a Conduction abnormality: complete right bundle branch block or I◦ atrioventricular block.
Table 2
Baseline echocardiographic parameters in patients with and without latent LVOT obstructions.
All (n = 64) Latent LVOT obstruction (+) (n = 40) Latent LVOT obstruction (−) (n = 24) p-Value
LAD, mm 35.4 ± 5.1 35.1 ± 4.9 35.8 ± 5.4 0.6
AoD,  mm 33.0 ± 3.9 32.5 ± 3.9 33.8 ± 4.0 0.20
LVEDD, mm 48.7 ± 5.7 48.4 ± 5.9 49.1 ± 5.6 0.64
LVESD, mm 28.4 ± 5.0 27.6 ± 5.0 29.6 ± 5.0 0.14
Ejection fraction, % 70.4 ± 5.7 72.0 ± 5.0 67.8 ± 5.9 0.0043
LVOT  velocity at rest, m/s 1.15 ± 0.26 1.23 ± 0.24 1.03 ± 0.24 0.0016
LVOT  velocity during Valsalva, m/s  1.20 ± 0.30 1.31 ± 0.27 1.03 ± 0.27 0.0002
E/A  0.7 ± 0.2 0.74 ± 0.18 0.75 ± 0.23 0.84
E/e′ 11.0 ± 3.8 11.7 ± 3.7 9.8 ± 3.6 0.05
Mid  IVS, mm 15.3 ± 2.6 10.1 ± 2.4 9.4 ± 1.7 0.22
Upper IVS, mm 15.3 ± 2.6 17.0 ± 2.0 16.0 ± 1.9 0.06
LVOT  diam (end diastolic), mm 16.8 ± 3.4 16.5 ± 3.4 17.3 ± 3.3 0.33
LVOT  diam (end systolic), mm 14.4 ± 3.2 13.4 ± 2.7 16.1 ± 3.4 0.0008
˛  (end diastolic), mm 37.6 ± 7.2 36.8 ± 7.9 39.0 ± 5.7 0.23
˛  (end systolic), mm 31.9 ± 5.0 29.9 ± 4.2 35.2 ± 4.6 <0.0001
  (end diastolic),◦ 90 ± 11.7 89.8 ± 10.9 91.0 ± 13.1 0.67
  (end systolic),◦ 90 ± 15.8 90.8 ± 15.1 89.0 ± 17.2 0.66
PWT,  mm 9.7 ± 1.6 9.8 ± 1.8 9.5 ± 1.3 0.44
RWT,  mm 0.40 ± 0.07 0.41 ± 0.08 0.39 ± 0.66 0.32
LV  mass index, g/m2 108 ± 30 109 ± 32 106 ± 27 0.73
L r; LVE
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(VOT, left ventricular outﬂow tract; LAD, left atrial diameter; AoD, aortic diamete
imension; IVS, interventricular septum; PWT, left ventricular posterior wall thickn
f an LVOT obstruction during DSE. In fact, a maximum blood pres-
ure decrease of >20 mmHg  was observed during DSE in 15 out of
0 patients with an LVOT obstruction, while this was not observed
n any patients without an LVOT obstruction. In the subjects with
atent obstructions, palpitations also often occurred during DSE. As
xpected, SAM of the mitral valve (Fig. 2D) was observed at the peak
f the LVOT obstruction in all 40 subjects with a latent obstruc-
ion versus only 6/24 subjects (25%) without a latent obstruction
p < 0.0001).DD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic
WT, left ventricular relative wall thickness; LV, left ventricular.
Impact of beta-blockers on latent LVOT obstructions associated
with an SVS
In 8 patients from the SVS group, the DSE  was  repeated at
115 ± 77 days after starting the beta-blocker therapy (carvedilol:
n = 1, atenolol: n = 1, metoprolol: n = 1, bisoprolol: n = 5). Before
the treatment, all subjects had cardiac symptoms (chest pain:
n = 4, dyspnea: n = 1, presyncope: n = 1, palpitations: n = 2), but
the beta-blocker therapy improved (n = 2) or abolished (n = 6)
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Table  3
Clinical parameters and occurrence of SAM during DSE.
All (n = 64) Latent LVOT obstruction (+) (n = 40) Latent LVOT obstruction (−) (n = 24) p-Value
Resting HR, bpm 65 ± 9 67 ± 9 63 ± 10 0.12
Peak  HR, bpm 113 ± 21 114 ± 17 112 ± 26 0.78
Resting systolic BP, mmHg  134 ± 20 135 ± 17 133 ± 24 0.71
Peak  systolic BP, mmHg 155 ± 27 150 ± 23 164 ± 32 0.03*
Chest pain (%) 12 (19) 10 (25) 2 (8) 0.08
Palpitations (%) 54 (84) 37 (93) 17 (71) 0.02*
Other symptoms (%) 11 (17) 8 (20) 3 (13) 0.43
Occurrence of SAM (%) 46 (72) 40 (100) 6 (25) <0.0001*
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cSE, dobutamine stress echocardiography; LVOT, left ventricular outﬂow tract; HR,
* p < 0.05.
hose symptoms. Beta-blockers reduced the peak heart rate from
10 ± 15 bpm (before treatment) to 90 ± 16 bpm (p = 0.0217) and
he peak LVOT gradient from 142 ± 65 mmHg  to 65 ± 49 mmHg
p = 0.0187), despite a higher mean infusion rate of the dobutamine
ompared with that before the treatment (36.3 ± 5.2 g/kg/min
ersus 23.8 ± 9.2 g/kg/min, p = 0.0047).
eproducibility of the 2D-based and RT3D-based “˛” distance
The 2D-based “˛” distance during end-systole was  measured
ndependently by two cardiologists. Analysis of the measurements
emonstrated a high interobserver congruence. The bias (mean
ifference) of the “˛” distance was 0.23 mm,  while the mini-
um  and maximum repeatability coefﬁcient values for 95% of the
atients were −0.56 and 1.02 mm,  respectively. The intraobserver
eproducibility was also high, with a bias of −0.07 mm,  while the
inimum and maximum repeatability coefﬁcient values for 95% of
he patients were −0.51 and 0.38 mm,  respectively.
The RT3D-based systolic “˛” distance was 34.0 ± 4.5 mm,  which
as similar to the distance of 32.8 ± 4.6 mm measured on the
-dimensional images in the apical three-chamber view (Fig. 3,
 = 0.2789). Reproducibility of the RT3D measurements was  also
igh, with a bias of 1.24 mm,  while the minimum and maximum of
he repeatability coefﬁcient for 95% of the patients was −1.14 and
.62 mm,  respectively.
iscussion
ain ﬁndings
The present study revealed that more than half of the SVS group
eveloped LVOT obstructions during the DSE. The occurrence of
atent obstructions was associated with the resting end-systolic
˛” distance, LVOT diameter, and LVEF, as well as with the LVOT
elocity at rest and during the Valsalva maneuver, although a mul-
ivariate analysis showed that the systolic distance “˛” and LVOT
elocity at rest were the only signiﬁcant predictors of a latent LVOT
bstruction in the SVS group.
VOT obstructions during DSE
Recent reports have indicated that LVOT obstructions become
pparent during a dobutamine infusion or exercise testing in
5–50% of patients with non-obstructive hypertrophic cardiomy-
pathy (HCM) [7,14–16]. There have also been several case reports
bout such latent LVOT obstructions in persons with an SVS [4,5],
ut its actual prevalence is unclear. In the present prospective
tudy, 62.5% of the SVS group developed LVOT obstructions dur-
ng the DSE. This high prevalence of latent obstructions in the
resent study population may  have been related to the enroll-
ent of subjects with various cardiac symptoms and ECG or
hest X-ray abnormalities [6]. It may  also be testimony to the rate; BP, blood pressure; SAM, systolic anterior motion of the mitral valve.
powerful provocative effect of dobutamine, which not only
increases contractility but also dramatically decreases the LV
volume. This possibility is supported by the fact that a higher preva-
lence of latent LVOT obstructions (50%) has been reported with DSE
[7] than with exercise testing [14–16].
Mechanism of LVOT obstructions associated with an SVS
Similar to the LVOT obstruction seen in patients with HOCM or
that induced by exercise or DSE in patients with non-obstructive
HCM, the latent obstruction in our SVS group was highly depend-
ent on SAM. In fact, SAM was  induced in all 40 of our subjects with
latent LVOT obstructions, whereas it was  only detected in 6/24 sub-
jects (25%) without latent obstructions. It is widely accepted that
LVOT obstructions in HOCM are based on two hydrodynamic forces,
which are the Venturi effect and the drag force [8–13]. In patients
with HOCM, LVOT narrowing and a hyperdynamic contraction cre-
ate a high velocity zone in the outﬂow tract due to the Venturi
effect, which draws the mitral leaﬂet toward the septum. In addi-
tion, papillary muscle displacement due to hypertrophy and mitral
leaﬂet enlargement increases the drag force on the mitral leaﬂets
in patients with HOCM [12,13,18,19]. These abnormalities lead to
redundancy of the mitral leaﬂets and protrusion into the ejection
ﬂow stream, which then pushes the leaﬂets toward the septum
and causes SAM (Fig. 4B) [8–13]. The present study suggested
that such a mechanism might also operate to cause latent LVOT
obstructions in persons with an SVS. We  found that our subjects
with latent LVOT obstructions had a shorter resting “˛” distance
at end-systole, smaller systolic LVOT diameter, and larger ejection
fraction than the subjects without latent obstructions. Narrowing
of the LVOT moves the mitral valve closer to the septum, making
it more likely that the blood ﬂow will strike the valve leaﬂet from
behind and push it into the septum. This effect may be enhanced
by a hyperdynamic contraction and decreased LV volume during a
dobutamine infusion. Furthermore, we found that the end-systolic
“˛” distance at rest was  one of the independent predictors of a latent
LVOT obstruction in our SVS group after an adjustment for sev-
eral echocardiographic variables. Several earlier studies [1,20,21]
have provided some insight into the mechanism underlying a short
“˛” distance associated with an SVS. Autopsy studies have con-
ﬁrmed that the SVS is caused by age-related anatomical changes,
including a rightward shift of the dilated ascending aorta, which
results in leftward kinking of the base of the ventricular septum
that then bulges into the LVOT [1,20,21]. The rightward shift of a
dilated ascending aorta could potentially push the anterior part of
the mitral annulus toward the papillary muscle, reducing the “˛”
distance. Thus, a decrease in the “˛” distance would predispose
one to a redundancy in the leaﬂets and/or chordae (Fig. 4C). These
anatomical changes associated with a short “˛” distance would also
increase the drag force acting on the mitral leaﬂets. Accordingly, the
anatomic changes (LVOT narrowing and displacement/redundancy
of the mitral valve) that lead to the LVOT obstruction may  be
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Fig. 4. Anatomical changes that predispose to systolic anterior motion (SAM) in a sigmoid ventricular septum (SVS) and hypertrophic obstructive cardiomyopathy (HOCM).
(A)  Diagram of a healthy control showing the “˛” distance (˛cont), LVOT diameter (LVOTD), and angle  (cont). (B) In a patient with HOCM, ˛HOCM is shorter than ˛cont because
myocardial hypertrophy causes anterior and medial displacement of the papillary muscle (solid arrow) [8] that reduces the distance between the tip of the posterior papillary
muscle  and the contralateral anterior mitral annulus. This could lead to a redundancy of the mitral leaﬂets. The increase in the septal thickness also reduces the LVOTD (open
arrow).  HOCM may  be equal to or smaller than cont [7]. (C) In a person with an SVS, the ascending aorta has enlarged and moved rightward with aging (solid gray arrow) [7]
reducing the size of sigmoid. This age-related change leads to kinking of the septal myocardium, which may  thicken the septal wall and reduce the LVOTD (open arrow). A
smaller  sigmoid could increase the drag force and narrowing of the LVOT and a thicker septal wall would move the mitral valve closer to the septum, making it more likely
that  blood ﬂow will strike the valve leaﬂet from behind and push it into the septum. In persons with an SVS, these abnormalities could predispose to SAM, but there is also
an  inﬂuence of the “˛” distance. A rightward shift of the dilated ascending aorta could push the contralateral anterior mitral annulus toward the papillary muscle (small
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bray  arrow). These anatomical changes would reduce the “˛” distance. If ˛sigmoid be
edundancy to be inﬂuenced by the ejection ﬂow stream and SAM will occur.
imilar in HOCM and SVS, although the structural basis may  differ
i.e. “hypertrophy” versus “age-related anatomical changes”).
imitations
This study had several limitations. First, this study was  a rel-
tively small single center study and therefore our results need
o be conﬁrmed in a larger patient population. Second, our sub-
ects could potentially have included patients with HCM. Magnetic
esource imaging or gene phenotypes may  help with the differ-
ntiation between both, but practically it was difﬁcult to obtain
hese data in all patients. However, we believe that the quantita-
ive assessment using our 4 SVS criteria and the exclusion criteria
or asymmetric septal hypertrophy could have potentially excluded
he patients with HCM. Third, half of our subjects were symp-
omatic and dobutamine was used to identify LVOT obstructions, so
e may  have overestimated the prevalence of latent LVOT obstruc-
ions associated with SVS. Exercise stress testing would be a better
ethod for identifying LVOT obstructions that occur in daily life.
owever, an old age and poor physical condition meant that most
f the subjects were unable to perform exercise testing. Fourth, it
an be difﬁcult to identify the tip of the posterior papillary mus-
le in the apical 3-chamber view, which could lead to errors in
easuring the “˛” distance. However, we always employed the
est apical 3-chamber view for identifying the tip of the poste-
ior papillary muscle when measuring the “˛” distance, and we
onﬁrmed that our 2-dimensional data agreed well with the RT3D-
ased “˛” distance. Fifth, excluding subjects with a resting LVOTs sufﬁciently short, the mitral leaﬂets and chordae tendineae will develop enough
obstruction may  not be a logical way to investigate the possible
mechanism of latent obstructions associated with an SVS. While
approximately 30% of the HCM patients have HOCM [22,23], LVOT
obstructions at rest seemed to be much less frequent in the SVS
patients [only 1/78 subjects (1.2%) in our series], although the exact
prevalence remains unclear. In one of our subjects with a resting
obstruction, the echocardiographic parameters (  ˛ = 25.4 mm,  LVOT
peak pressure gradient = 74.7 mmHg, and ejection fraction = 68.7%)
were identical to or greater than those in the subjects with latent
LVOT obstructions, which may  reinforce our conclusions. Finally,
the prognosis of an SVS associated with a latent LVOT obstruc-
tion remains unclear. Future prospective studies will be needed
to clarify these issues.
Clinical implications
The clinical signiﬁcance of an SVS associated with a latent LVOT
obstruction is still under debate. However, exertion, emotional
stress, and/or dehydration due to fever or loss of appetite could
reduce the LV chamber volume and the “˛” distance, thus possibly
predisposing patients to LVOT obstructions. Since the prevalence
of latent LVOT obstructions in our SVS group was  higher than
expected, attention should be paid to SVSs (especially if they
are associated with a short “˛” distance) due to the possibil-
ity of a latent LVOT obstruction. As previously reported [4,5,24],
beta-blockers or class I antiarrhythmic drugs may be effective for
patients with an SVS who have cardiac symptoms and/or a short “˛”
distance. Although we only investigated 8 subjects, we  found that
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[24] Hamada M,  Shigematsu Y, Inaba S, Aono J, Ikeda S, Watanabe K, Ogimoto A,A. Tano et al. / Journal of 
eta-blockers decreased the heart rate and LVOT pressure gradi-
nt during DSE, and simultaneously improved or eliminated their
ardiac symptoms such as chest pain or dyspnea. Although a study
onﬁrmed that an SVS is associated with a relatively benign prog-
osis [1,2], our ﬁndings provide useful information for improving
he quality of life of symptomatic patients with an SVS. In addition,
ur ﬁndings may  become more clinically relevant with the aging of
he societies in developed countries.
onclusion
About 60% of our subjects with an SVS developed a latent LVOT
bstruction during DSE, suggesting that they may  potentially suffer
rom an LVOT obstruction under certain conditions in daily life. Our
chocardiographic parameter (the end-systolic “˛” distance, i.e. the
istance between the tip of the posterior papillary muscle and the
ontralateral anterior mitral annulus in the apical three-chamber
iew at rest) was signiﬁcantly correlated with the occurrence of a
atent LVOT obstruction and may  be associated with the mechanism
f the obstruction.
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